Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8342425 | 0.74 | PDE4B (0.70) | PDE4B | |
| SCHEMBL4335557 | 0.73 | PDE4B (0.80) | PDE4B | |
| SCHEMBL3428110 | 0.73 | PDE4B (0.69) | PDE4BJAK1JAK2TYK2JAK3 | |
| SCHEMBL5962809 | 0.73 | PDE4B (0.53) | PDE4BDYRK1A | |
| SCHEMBL5962847 | 0.72 | PDE4B (0.52) | PDE4BJAK1JAK2TYK2JAK3 | |
| SCHEMBL2773376 | 0.70 | PDE4B (1.00) | PDE4BJAK1JAK3 | |
| SCHEMBL4334198 | 0.70 | PDE4B (0.85) | PDE4B | |
| SCHEMBL4341843 | 0.69 | PDE4B (0.74) | PDE4B | |
| SCHEMBL4332522 | 0.68 | PDE4B (0.85) | PDE4B | |
| SCHEMBL13705858 | 0.67 | LMNA (0.56) | PDE4BJAK1JAK2TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089375-A1 | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089375-A1 | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | PDE5A, PDE3B, PDE4A | PDE4B 4/4885DYRK1A 2986/4885JAK1 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.